GlassScriptPhysician profile
Jill Sisselman
NPI 1295895480
$6,248.49
in general payments reported to CMS, 2019-2025
38 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $811 · 2021: $471 · 2022: $420 · 2023: $717 · 2024: $1,620 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,203.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $627.58 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $480.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $335.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $318.21 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.78 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $217.96 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $192.79 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $192.00 | 2020-2025 | |
| Lilly USA, LLC | $150.76 | 2019-2025 | Mounjaro, Zepbound |
| Stryker Corporation | $147.94 | 2024 | Mako |
| Daiichi Sankyo INC. | $121.41 | 2020-2024 | Injectafer |
| Pfizer INC. | $114.48 | 2022-2025 | |
| Amarin Pharma, INC. | $94.63 | 2019-2023 | |
| Abbvie INC. | $70.01 | 2021-2023 | Qulipta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Sisselman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.